PubMed:21421994 / 1328-1499 JSONTXT

Annnotations TAB JSON ListView MergeView

Glycan-Motif

Id Subject Object Predicate Lexical cue
T5 5-12 https://glytoucan.org/Structures/Glycans/G70323CJ denotes mannose

GlyCosmos6-Glycan-Motif-Image

Id Subject Object Predicate Lexical cue image
T5 5-12 Glycan_Motif denotes mannose https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G70323CJ

GlyCosmos6-Glycan-Motif-Structure

Id Subject Object Predicate Lexical cue
T5 5-12 https://glytoucan.org/Structures/Glycans/G70323CJ denotes mannose

GlycoBiology-FMA

Id Subject Object Predicate Lexical cue
_T31 5-12 FMAID:82801 denotes mannose
_T32 5-12 FMAID:196796 denotes mannose
_T33 160-170 FMAID:167180 denotes antibodies

GO-MF

Id Subject Object Predicate Lexical cue
T3 160-170 http://purl.obolibrary.org/obo/GO_0003823 denotes antibodies

sentences

Id Subject Object Predicate Lexical cue
TextSentencer_T9 0-171 Sentence denotes High-mannose content of therapeutic Mabs should be considered an important product quality attribute which may affect pharmacokinetic properties of therapeutic antibodies.
T9 0-171 Sentence denotes High-mannose content of therapeutic Mabs should be considered an important product quality attribute which may affect pharmacokinetic properties of therapeutic antibodies.
T9 0-171 Sentence denotes High-mannose content of therapeutic Mabs should be considered an important product quality attribute which may affect pharmacokinetic properties of therapeutic antibodies.